What this study is
The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.
What's being tested
- Music intervention
Intervention · OTHER
Each GBM study participant in Arm A will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be curated by a board-certified music therapist. Arm B participants will receive curated playlists of music created by a music therapist. Participants will then listen to the curated music playlists on the participant's own device twice per week. All participants will complete a total of 16 music therapy sessions, scheduled twice per week over 8 weeks. Each session will last approximately 30 minutes.
Study details
- Official title
- Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions
- Glioblastoma (GBM)
- Enrolling
- 35 people
- Starts
- 2026-05-26
- Est. completion
- 2029-02-28
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Glioblastoma
- Cognitive capacity to respond to surveys
- Access to computer and web access
- Ability to attend virtual music therapy sessions
- Audibly process music
- Proficient in English
You can't join if
- Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
- A life expectancy of less than 6 months.
- Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openOncology- Broadway
Baltimore, Maryland, United States
- Matthias Holdhoff, MD. PhD. · Contact410-955--8837bcp-iis@jh.edu
Recruiting
Study team
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID J2556
Principal investigator
Matthias Holdhoff, MD, PhD.
Johns Hopkins -Sidney Kimmel Cancer Center
Principal investigator
Grace Tobin, MD
Johns Hopkins University
CONTACT
Principal Investigator- Matthias Holdhoff, MD, PhD.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.